We hypothesized that FRS2-FGFR interactions constitute a potentially druggable PPI with clinical relevance related to oncogenic signaling through FGFRs, where oncogenic alterations including amplification, mutation and fusion are common across human cancers [9–18]. This evidence concerns the gene FRS2 and cancer.